NovaBay Pharmaceuticals to Present at the Virtual Life Sciences Investor Forum

EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company developing and commercializing high-quality, scientifically formulated eyecare and skincare products, announces that management will present at the Virtual Life Sciences Investor Forum on Thursday, September 15, 2022 at 1:00 p.m. Eastern time (10:00 a.m. Pacific Time). Management will be holding investor one-on-one meetings on … [Read more…]

Virtuoso Surgical Announces First Public Offering of Common Stock to Advance its Revolutionary Robotic System for Endoscopic Surgery

NASHVILLE, Tenn.–(BUSINESS WIRE)–Virtuoso Surgical, Inc., a Nashville-based medical device company, announced today that its $20 million stock offering has become effective after review by the United States Securities and Exchange Commission and the Financial Industry Regulatory Authority. Virtuoso Surgical has developed a robotic surgery system that radically improves minimally invasive endoscopic surgery. Virtuoso uses patented … [Read more…]

SpectrumX Announces Significant Updates at Knutsford Production Facility

Critical upgrades allow the Company to produce SPC-069 drug substance for clinical trials Other new additions to the facility include dedicated quality control room, microbiology laboratory and office space KNUTSFORD, England–(BUSINESS WIRE)–SpectrumX, a UK-based healthcare and pharmaceutical company, announced today that recent upgrades at its state-of-the-art production facility in Knutsford, Cheshire, will allow the Company … [Read more…]

Alnylam Announces Pricing of Offering of $900 Million Convertible Senior Notes

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (“Alnylam”) (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the pricing of its previously announced private offering of $900 million aggregate principal amount of 1.00% convertible senior notes due 2027 (the “notes”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act … [Read more…]

Within3 Announces the Evolution of Industry-First Insights Management Platform

The amplified iteration of the platform transforms the potential for market visibility, research collaboration and business decision-making in life science CLEVELAND & LONDON–(BUSINESS WIRE)–Within3 announces new enhancements to its industry-first insights management platform for pharmaceutical and medical device companies. With more than 40 engagement applications across the platform, life science organizations can now better understand … [Read more…]

H.I.G. Capital Completes Recapitalization of Navitas Life Sciences

MIAMI–(BUSINESS WIRE)–#BlueChipClients–H.I.G. Capital (“H.I.G.”), a leading global alternative investment firm with over $50 billion of equity capital under management, is pleased to announce that one of its affiliates has completed the recapitalization of Navitas Life Sciences (“Navitas” or the “Company”). Headquartered in Princeton, NJ, Navitas is a global technology-enabled clinical research organization (CRO) providing outsourced … [Read more…]

Global EMC Filtration Market (2022 to 2027) – Increasing Adoption of Electric Vehicles Presents Opportunities – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “EMC Filtration Market by Product Type (EMC Filters (1-Phase EMC Filters, 3-Phase EMC Filters, DC Filters, IEC Inlets, Chokes), Power Quality Filters (Passive Harmonic Filters, Active Harmonic Filters, Output Filters, Reactors)) – Global Forecast to 2027” report has been added to ResearchAndMarkets.com’s offering. The EMC filtration market is expected to grow from USD … [Read more…]

Revitalist and Wake Network Enter Joint Venture Offering National and International Access to Psychedelics for Veterans

VANCOUVER, British Columbia–(BUSINESS WIRE)–#education–REVITALIST LIFESTYLE AND WELLNESS LTD. (“Revitalist” or the “Company”) (CSE: CALM) (OTCQB: RVLWF) (FSE: 4DO), Revitalist and Wake Network, Inc. will now be jointly offering ketamine infusions in the United States and psilocybin clinical retreats internationally with a special focus on Veteran’s ethical need for access, establishing the world’s first international center … [Read more…]

One Biosciences Initiates LARYCARE Clinical Study, Its Second Discovery Program

The LARYCARE study aims at discovering new predictive biomarkers to treatment response and at developing new potential precision therapies in the larynx and hypopharynx carcinoma This study follows One Biosciences’ first discovery program initiated a year ago in partnership with Institut Curie investigating high-grade serous ovarian cancer The initiation of this study follows the completion … [Read more…]

ONWARD Reports Positive Topline Results from a Pivotal Study to Restore Arm and Hand Function in People With Spinal Cord Injury

Up-LIFT study achieves primary endpoint: Statistically significant and clinically meaningful improvement in upper extremity strength and functioni Improvement in arm and hand function is the highest priority among people with tetraplegiaii Up-LIFT is the first large-scale clinical study of non-invasive spinal cord stimulation technology ONWARD plans to submit for marketing approval in the U.S. and … [Read more…]